研究概要
(1) 背景:HNSCC 是一种高度异质且易复发的癌症。
中文摘要
(1) 背景:HNSCC 是一种高度异质且易复发的癌症。我们旨在通过功能性筛选生成靶向 HER1/表皮生长因子受体 (EGFR) 的嵌合抗原受体 (CAR)-NK-92 细胞,以扩展针对 HNSCC 的免疫工具库。(2) 方法:在不同共培养模型中,对选定的 CAR-NK-92 细胞候选者进行测试,评估其增强靶细胞减少、CD107a 表达和 IFN 分泌的能力。对于代表性 HNSCC 模型,采用 EpCAM 分选方法生成患者来源的原发性 HNSCC (pHNSCC) 细胞系,以消除发现的高比例非恶性细胞。(3) 结果:2D 和 3D 球体共培养实验显示,抗 HER1 CAR-NK-92 细胞有效消除了 SCC 细胞系和原发性 HNSCC (pHNSCC) 细胞。肿瘤模型与抗 HER1 CAR-NK-92 细胞共培养导致 NK-92 细胞脱颗粒和 IFN 分泌增强,以及靶细胞凋亡。此外,剩余的 pHNSCC 细胞显示 putative 癌症干细胞标志物 CD44v6 表达上调。(4) 结论:这些结果突出了 CAR-NK 细胞疗法在 HNSCC 中的前景,以及可能有必要靶向多种肿瘤相关抗原以降低目前的高复发率。
展开英文摘要原文
(1) Background: HNSCC is a highly heterogeneous and relapse-prone form of cancer. We aimed to expand the immunological tool kit against HNSCC by conducting a functional screen to generate chimeric antigen receptor (CAR)-NK-92 cells that target HER1/epidermal growth factor receptor (EGFR). (2) Methods: Selected CAR-NK-92 cell candidates were tested for enhanced reduction of target cells, CD107a expression and IFN secretion in different co-culture models. For representative HNSCC models, patient-derived primary HNSCC (pHNSCC) cell lines were generated by employing an EpCAM-sorting approach to eliminate the high percentage of non-malignant cells found. (3) Results: 2D and 3D spheroid co-culture experiments showed that anti-HER1 CAR-NK-92 cells effectively eliminated SCC cell lines and primary HNSCC (pHNSCC) cells. Co-culture of tumor models with anti-HER1 CAR-NK-92 cells led to enhanced degranulation and IFN secretion of NK-92 cells and apoptosis of target cells. Furthermore, remaining pHNSCC cells showed upregulated expression of putative cancer stem cell marker CD44v6. (4) Conclusions: These results highlight the promising potential of CAR-NK cell therapy in HNSCC and the likely necessity to target multiple tumor-associated antigens to reduce currently high relapse rates.
论文信息
- 作者
- Nowak J、Bentele M、Kutle I、Zimmermann K、Lühmann JL、Steinemann D、Kloess S、Koehl U
- 单位
- Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.Germany
- 期刊
- Cancers2023 Jun 13